Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1

Conditions

Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Ovarian Neoplasms 1Neoplasms 1Metastatic Castration-sensitive Prostate Cancer 1

Interventions

Carboplatin 36Cisplatin 32pembrolizumab 29Paclitaxel 29Pemetrexed 22Gemcitabine 21Nivolumab 19Dexamethasone 17Rituximab 16Fluorouracil 13Docetaxel 13Ipilimumab 12Capecitabine 12durvalumab 11Cyclophosphamide 11atezolizumab 10130-nm albumin-bound paclitaxel 10olaparib 9Trastuzumab 9Lenalidomide 9Doxorubicin 9Cytarabine 9Bevacizumab 9daratumumab 8Oxaliplatin 8Bortezomib 8Vinorelbine 7Prednisone 7Leucovorin 7venetoclax 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × niraparib × Clear all
NCT04497844 2026-05-11

AMPLITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
696 enrolled 15 charts 1 FDA
Genitourinary

Metastatic Castration-sensitive Prostate Cancer

NCT03748641 2026-05-08

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Tesaro, Inc.

Phase 3 Active not recruiting
733 enrolled 21 charts 1 FDA
Gynecologic

Ovarian Neoplasms

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting
785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡